adMare
News
August 25 2023
Thryv Therapeutics Announces Positive Results from the WAVE 1 Proof of Concept Study.
August 24 2023
adMare BioInnovations invites early-career science professionals to apply to the BioInnovation Scientist (BIS) Program: Foundations Cohort II
August 15 2023
Thryv Therapeutics announces FDA clearance for Phase 1 Study of THRV-1257 in Anaplastic Thyroid Cancer and acceptance of Late-Breaking Poster Presentation at American Thyroid Association Meeting.
August 10 2023
Novo Nordisk to acquire Inversago Pharma to develop new therapies for people living with obesity, diabetes and other serious metabolic diseases
July 24 2023
Specific Biologics Strengthens Scientific Advisory Board with Appointment of Tirtha Chakraborty, Ph.D. and Mike Nicholson, Ph.D.
July 17 2023
Landmark Report Published on the Status of Inclusion, Diversity, Equity and Accessibility (IDEA) in Canada’s Life Sciences Sector
July 04 2023
CPDC Funds Research at Simon Fraser University for Developing
an LAT1-targeting Pet Tracer for Imaging Cancer
July 04 2023
Applications Now Open for Cohort VI of the adMare Academy Executive Institute Program
June 29 2023
Domain Therapeutics announces nomination of best-in-class CCR8 antibody candidate, DT-7012, further strengthening its unique portfolio of GPCR-targeting immunotherapies
June 15 2023
Award to provide US$2 million to support Zucara’s planned Phase 2a ZONE trial, with first patient dosing expected in Q3 2023
June 08 2023
Thryv Therapeutics Announces Significant Progress Across all Programs within its SGK1 Inhibitor Portfolio and the Closing of a Convertible Note Financing with Investissement Québec
Newsletter
Stay up to date on the
latest adMare news
Vancouver Innovation Centre
2405 Wesbrook Mall, 4th Floor
Vancouver, British Columbia, Canada
V6T 1Z3
T. 604.827.1147
Montreal Innovation Centre
7171 Frederick-Banting
Montréal, Québec, Canada
H4S 1Z9
T. 514.375.3334
Toronto Office
MaRS Centre, West Tower
661 University Ave., Suite 405
Toronto, Ontario, Canada
M5G 1M1
